{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Acute GvHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Chronic extensive GvHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Chronic extensive and persistent GvHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Recipients will be monitored for Grade 2 to 4 graft vs host disease (GvHD). The outcome is reported as the number of transplant recipients who experienced acute GvHD grades 2 to 4, the number of transplant recipients who experienced chronic and extensive GvHD. In addition, the number of transplant recipients with chronic and extensive GvHD that was refractory to treatment (\"persistent\") is reported. Per protocol, the result for chronic extensive and persistent GvHD is based on the subset of participants that had chronic and extensive GvHD.","groups":[{"description":"TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)\n\nTotal body irradiation (TBI): Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning\n\nAnti-thymocyte globulin (ATG): Given intravenous (IV), Dose 1.5 mg/kg x 5 days\n\nTacrolimus: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)\n\nMycophenolate mofetil (MMF): Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.\n\nTotal lymphoid irradiation (TLI): 9 x 120 cGy over 11 days","id":"OG000","title":"TBI+TLI"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Per protocol, the outcome for chronic extensive and persistent GvHD is based on the subset of participants that had chronic and extensive GvHD.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Graft vs Host Disease (GvHD)","type":"SECONDARY","unitOfMeasure":"Participants"}